Efficacy and safety of dostarlimab in patients (pts) with mismatch repair deficient (dMMR) solid tumors: Analysis of 2 cohorts in the GARNET study

Autor: Thierry Andre, Dominique Berton, Giuseppe Curigliano, Begona Jimenez-Rodriguez, Susan Ellard, Adriano Gravina, Rowan Miller, Anna Tinker, Andrea Jewell, Joanna Pikiel, Ana Oaknin, Tao Duan, Sybil Zildjian, Eleftherios Zografos, Jennifer Taylor Veneris, Susana N. Banerjee

Publikováno v: Journal of Clinical Oncology. 40:2587-2587

2587 Background: Dostarlimab is a programmed death 1 (PD-1) inhibitor approved in the US as a monotherapy in pts with dMMR solid tumors that have progressed on or after prior treatment, with no satisfactory alternative treatment options; or dMMR adva

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1ab8667fd744c738693df611830f132c
https://doi.org/10.1200/jco.2022.40.16_suppl.2587

Detection of TP53 and PIK3CA Mutations in Circulating Tumor DNA Using Next-Generation Sequencing in the Screening Process for Early Breast Cancer Diagnosis

Autor: Luis Vicioso, Frank Holtrup, Begoña Bermejo, Frederick S. Jones, Johannes Fredebohm, Begona Jimenez Rodriguez, Matthew B. Ryder, Martina Alvarez, Emilio Alba, Alicia Garrido Aranda, Casilda Llacer Perez, Cristina Hernando, Ana Julve Parreño, Ana Lluch, Gema Diaz Córdoba, María Isabel Queipo-Ortuño

Publikováno v: Journal of Clinical Medicine
Volume 8
Issue 8
Journal of Clinical Medicine, Vol 8, Iss 8, p 1183 (2019)
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname

Circulating tumor DNA (ctDNA) has emerged as a non-invasive &ldquo
liquid biopsy&rdquo
for early breast cancer diagnosis. We evaluated the suitability of ctDNA analysis in the diagnosis of early breast cancer after mammography findings, com

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47fb9e4ff371332cda70f20ab96382d5
https://hdl.handle.net/10668/14381

Prediction of early progression (EP) to CDKIs first line treatment in ER+/HER2- metastatic breast cancer (MBC) using machine learning

Autor: Bella Pajares, Alfonso Sánchez-Muñoz, Héctor Mesa, Tamara Diaz Redondo, José M. Jerez, Enrique Saez Lara, Antonia Márquez, Ester Villar, Francisco Carabantes, Sofía Ruíz, Emilio Alba, Pablo Rodriguez-Brazzarola, Laura Galvez Carvajal, Maria-Jose Bermejo-Perez, Maria Emilia Dominguez-Recio, Irene López, Ana Godoy, Nuria Ribelles, Leo Franco, Begona Jimenez Rodriguez

Publikováno v: Journal of Clinical Oncology. 38:e13040-e13040

e13040 Background: The treatment of luminal MBC has undergone a substantial change with the use of cyclin dependent kinase 4/6 inhibitors (CDKIs). Nevertheless, there is not a clearly defined subgroup of patients who do not initially respond to CDKIs

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6a938d415e51b0ee9186447e8dcca8bd
https://doi.org/10.1200/jco.2020.38.15_suppl.e13040

Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial

Autor: Javier Salvador Bofill, Fernando Moreno Anton, Cesar Augusto Rodriguez Sanchez, Elena Galve Calvo, Cristina Hernando Melia, Eva Maria Ciruelos Gil, Maria Vidal, Begoña Jiménez-Rodriguez, Luis De la Cruz Merino, Noelia Martínez Jañez, Rafael Villanueva Vazquez, Ruben de Toro Salas, Antonio Anton Torres, Isabel Manuela Alvarez Lopez, Joaquin Gavila Gregori, Vanesa Quiroga Garcia, Elena Vicente Rubio, Juan De la Haba-Rodriguez, Santiago Gonzalez-Santiago, Nieves Diaz Fernandez, Agusti Barnadas Molins, Blanca Cantos Sanchez de Ibargüen, Juan Ignacio Delgado Mingorance, Meritxell Bellet Ezquerra, Sonia de Casa, Asuncion Gimeno, Miguel Martin

Publikováno v: Breast, Vol 66, Iss , Pp 77-84 (2022)

Background: Breast cancer is the most common malignancy and the second leading cause of cancer-related mortality in Spanish women. Ribociclib in combination with endocrine therapy (ET) has shown superiority in prolonging survival in patients with hor

Externí odkaz: https://doaj.org/article/dad241cf2af94fb9adb70457754b6c11

Different pCR rates according PAM50 defined subtypes in HER2 positive early breast cancer treated with neoadjuvant pertuzumab and trastuzumab

Autor: Marta Amérigo Góngora, Nuria Ribelles, Maria Carmen Álamo de la Gala, Martina Alvarez, Aleix Prat, José M. Jerez, T. Pascual, Aurora Laborda Illanez, Rocío Lavado-Valenzuela, Luis Vicioso, Javier Pascual, Emilio Alba, Cristina Morales-Estevez, Fernando Galvez Montosa, Alejandro Falcon, Tamara Diaz-Redondo, Aranzazu Fernandez, Begona Jimenez Rodriguez, Nuria Chic, Macarena González Guerrero

Publikováno v: Journal of Clinical Oncology. 36:e12634-e12634

e12634Background: We aim to compare the benefit of adding pertuzumab (P) to the standard neoadjuvant treatment with trastuzumab (T) in patients (pt) with early immunohistochemically (IHC) defined H...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::32ba2c576cf20f28bc750e9c4883c282
https://doi.org/10.1200/jco.2018.36.15_suppl.e12634